ESMO 2023 Insights: "innovaTV 301/ENGOT-cx12/GOG-3057 Study - Tisotumab Vedotin vs. Investigator’s Choice of Chemo in 2L/3L Recurrent or Metastatic Cervical Cancer"

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

ESMO 2023 Insights: "innovaTV 301/ENGOT-cx12/GOG-3057 Study - Tisotumab Vedotin vs. Investigator’s Choice of Chemo in 2L/3L Recurrent or Metastatic Cervical Cancer"

By Insights from 2023 ESMO Annual Meeting FEATURING Susana Banerjee

61 views

December 13, 2023

0 Comments

First-line Maintenance Therapy for BRCAm Advanced Ovarian Cancer Fol…

Feat. S. Lewin

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn

Cancer Screening Molecular Tools

17:50

AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde

06:07

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Summary: "Key Updates in Gynecological Cancers"

Feat. M. Raza Mirza

04:02

Total Health

2024 Updates in Cervical Cancer

Feat. T. Tillmanns

15:14

Brian Slomovitz

Update in Vulvar and Vaginal Cancer

07:56

Fengting Yan

Year in Review: Cervical Cancer

13:41

UCLA Health

2024 Updates in Locally Advanced Cervical Cancer

Feat. D. Chase

06:46

Total Health

Recent Highlights in Cervical Cancer

Feat. B. Slomovitz

12:45

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "The GCIG INTERLACE Randomised Phase 3 Tria…

Feat. M. McCormack

44:59

Fred Hutch 13th Annual Comprehensive Hematology & Oncology Review Course

Updates on Cervical and Endometrial Cancers

Feat. K. Pennington

05:31

Insights from 2024 SGO Annual Meeting

SGO 2024 Insights: "Impact of Maintenance Bevacizumab Following…

Feat. M. Kuznicki

04:58

Oncology Data Advisor

Tisotumab Vedotin for Metastatic Cervical Cancer: Updates From ESMO …

Feat. B. Slomovitz

10:27

Robert McBane

2023 ISTH Insights: "The EVE Trial - Extending VTE Secondary Pr…

11:37

UCLA Health

Recurrent Cervical Cancer Updates

Feat. R. Salani

12:21

Insights from 2024 ESGO Annual Meeting

ESGO 2024 Insights: "PARP Inhibitor Resistance Mechanisms in Gy…

Feat. V. Heinzelmann-Schwarz

07:03

Insights from 2024 SGO Annual Meeting

SGO 2024 Insights: "innovaTV 301/ENGOT-cx12/GOG-3057 Study - Ef…

Feat. B. Slomovitz

11:02

SGO 2023 Conference Coverage on VuMedi

Chemoradiation for Stage IB3 Cervical Cancer

Feat. J. Mayadev

07:05

Insights from 2024 ESGO Annual Meeting

ESGO 2024 Insights: "Understanding and Targeting BRCA & HRD…

Feat. V. Heinzelmann-Schwarz

11:10

Insights from 2023 ESMO Annual Meeting

ESMO 2023 Insights: "KEYNOTE-A18 Study - Pembro + CRT for High-…

Feat. D. Lorusso

08:24

Hope Cottrill

Login

Login

Join VuMedi

ESMO 2023 Insights: "innovaTV 301/ENGOT-cx12/GOG-3057 Study - Tisotumab Vedotin vs. Investigator’s Choice of Chemo in 2L/3L Recurrent or Metastatic Cervical Cancer"

Related Content